3 unchanged sentences
ADMA Biologics, Inc.
−Removed: President and Chief Executive Officer
+Added: Date:August 10, 2022
+Added: Title:President and Chief Executive Officer
+Added: Date:August 10, 2022
/s/ Brian Lenz
2 unchanged sentences
Exhibit Number
−Removed: Form of Warrant to Purchase Stock, in the form issued by the Company to various entities affiliated with Hayfin Services LLP, dated as of March 23, 2022 (incorporated by reference to Exhibit 4.13 to the
−Removed: Company’s Annual Report on Form 10-K, filed with the SEC on March 24, 2022.
−Removed: Credit Agreement and Guaranty, dated as of March 23, 2022, by and among the Company, Hayfin Services LLP and the lenders party thereto (incorporated by reference to Exhibit 10.24 to the Company’s Annual
−Removed: Report on Form 10-K, filed with the SEC on March 24, 2022).
−Removed: Security Agreement, dated as of March 23, 2022, by and among the Company, certain subsidiaries of the Company and Hayfin Services LLP (incorporated by reference to Exhibit 10.25 to the Company’s Annual
−Removed: Report on Form 10-K, filed with the SEC on March 24, 2022).
+Added: ADMA Biologics, Inc.
+Added: 2022 Equity Compensation Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2022).
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
2 unchanged sentences
Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended March 31, 2022, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) Condensed Consolidated Balance Sheets as
−Removed: of March 31, 2022 (Unaudited) and December 31, 2021, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2022 and 2021, (iii) Condensed Consolidated Statements of Changes in Stockholders’
−Removed: Equity (Unaudited) for the three months ended March 31, 2022 and 2021, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2022 and 2021, and (v) Notes to (Unaudited) Condensed
+Added: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended June 30, 2022, formatted in Extensible Business Reporting Language (XBRL):
+Added: (i) Condensed Consolidated Balance Sheets as of June
+Added: 30, 2022 (Unaudited) and December 31, 2021, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2022 and 2021, (iii) Condensed Consolidated Statements of Changes in Stockholders'
+Added: Equity (Unaudited) for the three and six months ended June 30, 2022 and 2021, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2022 and 2021, and (v) Notes to (Unaudited) Condensed
Consolidated Financial Statements.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.